China
Africa
Explore chapters and articles related to this topic
Daptomycin
Published in M. Lindsay Grayson, Sara E. Cosgrove, Suzanne M. Crowe, M. Lindsay Grayson, William Hope, James S. McCarthy, John Mills, Johan W. Mouton, David L. Paterson, Kucers’ The Use of Antibiotics, 2017
Anouk E. Muller, Inge C. Gyssens
The MIC for daptomycin (MIC range, 0.03–2 mg/l) against MSSA obtained between 1999 and 2006 was two to four times lower than for vancomycin and two to eight times lower than for linezolid (Hair and Keam, 2007). The new lipoglycopeptide dalbavancin is more potent than daptomycin. S. aureus daptomycin MIC distributions from 2006 com-pared with those of previous years did not show a “MIC creep” (Castanheira et al., 2008).
Enterococci: Resistance Update and Treatment Options
Published in Robert C. Owens, Lautenbach Ebbing, Antimicrobial Resistance, 2007
Telavancin, a long-acting lipoglycopeptide with multiple sites of action at the cell membrane and cell wall, has shown noninferiority versus standard therapy in Gram-positive CSSSI including MRSA; however, clinical data for VRE is not yet available (119,120).
Clinical efficacy and safety of novel lipoglycopeptides in the treatment of acute bacterial skin and skin structure infections: a systematic review and meta-analysis of randomized controlled trials
Published in Expert Review of Anti-infective Therapy, 2022
Chi-Kuei Hsu, Ching-Yi Chen, Wang-Chun Chen, Chien-Ming Chao, Chih-Cheng Lai
In this meta-analysis, eight RCTs were reviewed to compare lipoglycopeptides (dalbavancin, three RCTs; telavancin, three RCTs; oritavancin, two RCTs) with other antibiotic regimens in terms of efficacy and safety in the treatment of ABSSSIs [20–25,27,29]. Overall, lipoglycopeptides achieved a clinical response rate comparable to that of the comparators, as supported by the following evidence: First, the overall clinical response rate of lipoglycopeptides in the treatment of ABSSSIs was similar to that of the comparators at the ECE, EOT, and TOC assessments. Second, the clinical response rate of each lipoglycopeptide (dalbavancin, telavancin, and oritavancin) was comparable to that of the comparators. Third, the similarity in clinical response rate between lipoglycopeptides and comparators remained unchanged in the sensitivity test and various subgroup analyses (according to vancomycin or linezolid as the comparator, one or two doses of each lipoglycopeptide, and different pathogens including S. aureus [MSSA and MRSA] and Streptococcus spp.). The above findings were in line with those of previous meta-analyses of each lipoglycopeptide [36–39]. In summary, these findings indicate that lipoglycopeptides can be as effective as other antibiotics in the treatment of adult patients with ABSSSIs.
Successful dalbavancin use in preventing reactivation of Staphylococcus aureus liver abscess during pre-engraftment neutropenia after allogeneic hematopoietic stem cell transplantation
Published in Journal of Chemotherapy, 2021
Gianluca Dell’Orso, Maura Faraci, Stefano Giardino, Marcello Mariani, Alessio Mesini, Elio Castagnola
Dalbavancin is a lipoglycopeptide with in vitro activity against Gram-positive bacteria including S.aureus.3 In Europe it is approved for skin and soft tissue infections in adults as a single infusion of 1,500 mg or as 1,000 mg followed one week later by 500 mg,4 but repeated high doses resulted effective and well tolerated.5,6 In this patient the drug was chosen on the base of its activity and liver tissue penetration (at least in experimental models).7 Dalbavancin half-life allowed only 2 administrations in the pre-engraftment HSCT phase, which generally requires infusion of many drugs for support, including antibiotics.This strategy resulted effective and well tolerated. Even if further studies are needed, this case indicates that dalbavancin could result effective and safe for preventing reactivation of Gram-positive invasive infections during HSCT pre-engraftment neutropenia.
Novel developments in the treatment of acute bacterial skin and skin structure infections
Published in Expert Opinion on Pharmacotherapy, 2019
Rupal K. Jaffa, Kelly E. Pillinger, Danya Roshdy, Jacqueline A. Isip, Timothy R. Pasquale
Despite many advantages of these newer agents, there is still much to be learned about the new ABSSSI agents. Clinical trials leading to the approval of these medications measure outcomes after a short duration, without assessing long term outcomes. While safety endpoints were assessed in the clinical trials, robust safety data remains limited due to the relatively low numbers of patients who have received them. Additionally, given the relative newness of these agents, there are limited organism susceptibility data. Some agents, such as the lipoglycopeptide agents, have no commercially available susceptibility testing available. Vancomycin susceptibility is used as a surrogate marker to predict susceptibility to the lipoglycopeptides. While this is usually accurate, vancomycin susceptibility may not always correlate with oritavancin or telavancin susceptibility [58,59]. As the use of recently approved antibiotics expands, resistance patterns will likely change. However, given their limited use to date, it is difficult to predict how this change will occur and how quickly resistance will develop.